Gilead Sciences

Cheap Stocks for Your Portfolio in a Pricey Market

The stock market has been on a tear over the past two years. With the major indexes hitting multiyear highs recently, the value pickings are slim. But Motley Fool analyst Dan Caplinger highlights five stocks that still have attractive prices in this rising market.

The Five Best-Performing Biotech Stocks of 2011 -- So Far

Pharmaceuticals are facing big patent cliff problems this year, but several biotechnology stocks have been doing quite well: Their biologic drugs command high prices, tend become blockbusters, and -- perhaps most important -- are in far less danger from generic competition. Here are the big winners so far.

Vaginal Gel Helps Women Cut AIDS Risk

As the world hopes for an HIV vaccine following recent positive developments, a new study in South Africa shows that a vaginal gel made using Gilead Sciences' AIDS drug Viread cut HIV infections in women by as much as 50%.

Biotechs That Could Thrive with Health Reform

If the health care bills in Congress become law, the biotech sector may become one of the biggest beneficiaries. Standard & Poor's identifies six stocks and mutual funds that stand to benefit the most from the changes.